Answers are grounded in this paper and cite their sources.
The ‘new’ term ‘deprescribing’ was discussed in a recent editorial by Alldred,[1] where the difficulty in searching for research regarding cessation of medications due to the lack of a standardized term for it was highlighted. While deprescribing has been defined as medication cessation, the term is broader than simply cessation and encompasses the process of trial medication withdrawal. Deprescribing may include gaining a complete medication history, identifying medications for withdrawal, medication tapering and monitoring following cessation.[2,3] We agree with Alldred and previous authors[1,4] that use of the term deprescribing in future studies should be advocated to distinguish it from alternative terms ‘cessation’, ‘withdrawal’ and ‘discontinuation’, which are nonspecific and do not capture the process involved. The editorial by Alldred discussed some of the potential medical practitioner barriers to deprescribing before saying, ‘There is a paucity of research on the patient perspective of deprescribing’. They continue by suggesting this significant gap in the literature needs to be addressed. This has been a focus of work conducted by myself and colleagues. Firstly, we developed and validated the patients' attitudes towards deprescribing questionnaire[5] and then employed it in a population of mostly older people with multiple comorbidities.[6] We were able to quantify that over 90% of people would be willing to cease a medication if their doctor said it was possible. Interestingly, willingness to deprescribe was not associated with age, number of medications or number of comorbidities. This questionnaire also revealed that a majority of people would prefer face-to-face contact following medication cessation and would be comfortable with pharmacist involvement in deprescribing.[6] This study was followed by a systematic review of the potential patient barriers to and enablers of deprescribing.[7] The review involved qualitative and quantitative studies, and demonstrated the main barriers are fear of consequences (including withdrawal reactions, return of condition and nonspecific fears) and disagreeing that medication cessation is appropriate (e.g. feeling that the medication is still necessary, hope for future benefits). These barriers may be balanced by enablers including patient's dislike of medications or agreement that the medication is inappropriate. The process in which a medication will be withdrawn and the support provided (or perceived to be available) will influence a patient's willingness to deprescribe. Other influences identified included the patient's primary care physician, family and friends, and the media. We agree with Alldred's conclusion that strategies to effectively implement deprescribing frameworks need to be developed and tested. Knowledge of patients' attitudes towards deprescribing will aid in the development of protocols that may be employed in practice, particularly for approaching the topic of cessation with patients and what monitoring and follow-up should be provided. The Author(s) declare(s) that they have no conflicts of interest to disclose. This research received no specific grant from any funding agency in the public, commercial or not-for-profit sectors. ER and JP both worked on the article concept, drafting of manuscript and approval of final manuscript. All Authors state that they had complete access to the study data that support the publication.
No takes yet. Share an insight, caveat, or question.
Reeve et al. (2015) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: